14.27

1.64% 0.23

After Hours: 14.74 0.47 +3.29%

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $14.27, with a volume of 743.69K. It is up +1.64% in the last 24 hours and up +29.61% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Previous Close:

$14.04

Open:

$14.02

24h Volume:

743.69K

Relative Volume:

0.56

Market Cap:

$1.83B

Revenue:

Net Income/Loss:

$-42.76M

P/E Ratio:

-44.48

EPS:

-0.3208

Net Cash Flow:

$-42.09M

1W Performance:

+9.18%

1M Performance:

+29.61%

6M Performance:

+34.37%

1Y Performance:

+130.16%

1-Day Range:

$13.76

$14.33

1-Week Range:

$12.76

$14.33

52-Week Range:

$5.3801

$14.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2026-03-17

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	14.27	1.80B	0	-42.76M	-42.09M	-0.3208
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

Apr 13, 2026

Inflation Data: Is Trevi Therapeutics Inc a top pick in the sectorChart Signals & Safe Entry Trade Reports - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN

Apr 11, 2026

Apr 10, 2026

Trevi Therapeutics (TRVI) asks shareholders to approve stock-plan refresh and share increase - Stock Titan

Apr 10, 2026

Apr 09, 2026

Stock Market Recap: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn

Apr 09, 2026

Apr 06, 2026